Compile Data Set for Download or QSAR
Report error Found 40 Enz. Inhib. hit(s) with all data for entry = 12547
TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708495(3-(5-(5-(((3s,5s,7s)- adamantan-1- yl)amino)pentyl...)
Affinity DataIC50: 50nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708497(3-(5-(8-(((1s,3s)-adamantan- 1-yl)amino)octyl)-2-m...)
Affinity DataIC50: 180nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708498(3-(5-((7-(((3as, 6as)-hexahydro- 2,5-methanopental...)
Affinity DataIC50: 320nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708513(3-(5-((5-(((1r,3r, 5r,7r)-adamantan-2- yl)amino)pe...)
Affinity DataIC50: 420nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708509(3-(5-((5-(((3as, 6as)-hexahydro- 2,5-methanopental...)
Affinity DataIC50: 420nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708496(3-(5-((6-(((2R,3as,5S,6as)- hexahydro-2,5- methano...)
Affinity DataIC50: 460nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708517(3-(5-((2-(2-(2-(((2R,3as,5S, 6as)-hexahydro-2,5- m...)
Affinity DataIC50: 660nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708514(3-(5-((7-((1-((3r,5r,7r)- adamantan-1- yl)ethyl)am...)
Affinity DataIC50: 680nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708494(3-(5-((3-(((1r,3r, 5r,7r)-adamantan-2- yl)amino)pr...)
Affinity DataIC50: 700nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708505(3-(5-((2-(2-(((3as,6as)- hexahydro-2,5- methanopen...)
Affinity DataIC50: 780nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708492(3-(5-((7-(((1s,3s)-adamantan-1- yl)amino)heptyl)am...)
Affinity DataIC50: 950nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708511(3-(5-((4-(((1r,3r, 5r,7r)-adamantan-2- yl)amino)bu...)
Affinity DataIC50: 990nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708523(3-(5-(3-(4-(2-((1s,3s)- adamantan-1-yl) ethyl)pipe...)
Affinity DataIC50: 1.00E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708521(3-(5-((4-(2-((3r,5r,7r)- adamantan-1-yl) ethyl)pip...)
Affinity DataIC50: 1.00E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708506(3-(5-((7-(6-oxa-3- azabicyclo[3.1.1 ]heptan-3- yl)...)
Affinity DataIC50: 1.04E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708512(3-(5-((7-(((1SR,3RS, 5SR,7r)-3,5- dimethyladamanta...)
Affinity DataIC50: 1.05E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM76986(3-(5-amino-2-methyl-4-oxo-4H-quinazolin-3-yl)-pipe...)
Affinity DataIC50: 1.07E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708519(3-(5-((2-(4-(2-((3r,5r,7r)- adamantan-1-yl)ethyl)p...)
Affinity DataIC50: 1.20E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708493(3-(5-((3-(4-(2-((3r, 5r,7r)-adamantan-1- yl)ethyl)...)
Affinity DataIC50: 1.57E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708507(3-(5-((2-(4-(2-((3r,5r,7r)- adamantan-1-yl)ethyl)p...)
Affinity DataIC50: 1.72E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708500(3-(2-methyl-5- ((7-(4-methyl- 1,4-diazepan-1- yl)h...)
Affinity DataIC50: 1.80E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708525(3-(2-methyl-4-oxo-5- (piperazin-1-ylmethyl)quinazo...)
Affinity DataIC50: 1.84E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708520(3-(5-((2-(4-(4-((1s, 3s)-adamantan-1-yl) benzyl)pi...)
Affinity DataIC50: 1.98E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708526(3-(5-((2-(4- (((3r,5r,7r)-adamantan- 1-yl)methyl)p...)
Affinity DataIC50: 2.15E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708529(3-(5-(3-(4-(4-((3r,5r, 7r)-adamantan-1- yl)benzyl)...)
Affinity DataIC50: 2.24E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708524(3-(5-((4-(((3r,5r,7r)- adamantan-1-yl) methyl)pipe...)
Affinity DataIC50: 2.24E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708527(3-(5-((3-(4-(((1s,3s)-adamantan- 1-yl)methyl)piper...)
Affinity DataIC50: 2.40E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708499(3-(2-methyl-5-(8-(4- (4-methylpiperazin- 1-yl)pipe...)
Affinity DataIC50: 2.47E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708508(3-(2-methyl-5-((7-(4- morpholinopiperidin-1- yl)he...)
Affinity DataIC50: 2.48E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708510(3-(2-methyl-5-((7-(4- (oxetan-3-yl)piperazin-1- yl...)
Affinity DataIC50: 2.52E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708515(3-(5-((7-((4- fluorobicyclo[2.2.2] octan-1- yl)ami...)
Affinity DataIC50: 2.61E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708528(3-(5-((4-(4-((3r,5r,7r)- adamantan-1-yl)benzyl)pip...)
Affinity DataIC50: 2.75E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708491(3-(2-methyl-5-(8-(4- methylpiperazin-1- yl)oct-1-y...)
Affinity DataIC50: 2.80E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708516(3-(5-((7-(2,2-difluoro-7- azaspiro[3.5]nonan-7- yl...)
Affinity DataIC50: 2.80E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708504(3-(5-(((1s,3s)-adamantan- 1-yl)amino)-2-methyl-4- ...)
Affinity DataIC50: 2.82E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708518(3-(5-(3-(2-((3r,5r,7r)- adamantan-1-yl)ethyl)-3,6-...)
Affinity DataIC50: 3.24E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708503(3-(5-((2-(2-(((1s,3s)-adamantan-1- yl)amino)ethoxy...)
Affinity DataIC50: 3.34E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708501(3-(5-(8-(6-oxa-3- azabicyclo[3.1.1] heptan-3-yl)oc...)
Affinity DataIC50: 3.40E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708522(3-(5-((4-((1s,3s)-adamantane- 1-carbonyl)piperazin...)
Affinity DataIC50: 3.58E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent

TargetProtein cereblon(Human)
Gluetacs Therapeutics (Shanghai) Co.

US Patent
LigandPNGBDBM708502(3-(5-((7-hydroxyheptyl) amino)-2-methyl-4- oxoquin...)
Affinity DataIC50: 3.66E+3nMAssay Description:1. According to the instructions of the CEREBLON BINDING kits, the compounds to be tested of the present invention and lenalidomide were serially dil...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In Depth
Date in BDB:
5/7/2025
Entry Details
US Patent